BiPar Sciences is Drug Discovery in United States that focus on inhibitor candidate business. Founded in 2002. They cover business area such as developer, tumor-selective drug, multiple cancer type, -treat, metastatic triple-negative breast cancer, ovarian cancer, pancreatic cancer, an iodothyronine program, anti-tubulin property, healthcare provider, chemotherapy.
2002
( 24 years old in 2026 )
Inhibitor Candidate
-
400 Oyster Point Boulevard
Suite 200
South San Francisco, CA 94080
United States
Private
developertumor-selective drugmultiple cancer type-treatmetastatic triple-negative breast cancerovarian cancerpancreatic canceran iodothyronine programanti-tubulin propertyhealthcare providerchemotherapy
* We use standard office opening hours in near BiPar Sciences's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
BiPar Sciences is Drug Discovery business from United States that founded in 2002 (24 years old in 2026), BiPar Sciences business is focusing on Inhibitor Candidate.
BiPar Sciences headquarter office and corporate office address is located in 400 Oyster Point Boulevard Suite 200 South San Francisco, CA 94080 United States.
BiPar Sciences was founded in United States.
In 2026, BiPar Sciences is currently focus on inhibitor candidate sector.
Above is snippet of Google Trends for "inhibitor candidate" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with BiPar Sciences, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
